Akebia halts VOICE trial citing improved safety for Vafseo over ESAs
USRC and Akebia halted the VOICE trial due to improved safety outcomes with Vafseo compared to ESAs. The interim data indicates a significant reduction in hospitalizations, supporting the clinical profile of the anemia therapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day